Julie Andrews Buys Shares of RxSight, Inc.

Julie Andrews purchased 37,037 shares of RxSight, Inc. on June 17, 2026.

Written by EarningsIQ · Published Jun 19, 2026, 3:02 AM EDT · Updated Jun 20, 2026, 6:00 AM EDT

Key Points

Julie Andrews acquired 37,037 shares of RxSight, Inc. on June 17, 2026, with the stock priced at $4.73.
RxSight, Inc. has a market cap of approximately $195.8 million and a forward P/E ratio indicating unprofitability.
Analysts have set price targets for RxSight, Inc., with Needham reiterating a buy rating and a $13 target.

Julie Andrews bought 37,037 shares of RxSight, Inc. (NasdaqGM: RXST) on June 17, 2026. The stock is currently trading at $4.73.

Insider Buying and Selling at RxSight, Inc.

Julie Andrews wasn't the only one buying shares of RxSight, Inc. on June 17, 2026. Other insiders, including Tammenoms Bakker Juliet, Warner Robert Keith, Palmisano Robert, Link William PhD, Maniar Shweta, and Corley Jesse Anderson, each purchased 37,037 shares. None of these transactions were planned under Rule 10b5-1.

Other Institutional Activity in RxSight, Inc.

Several funds have adjusted their positions in RxSight, Inc. BlackRock, Inc. increased its holdings by 482,086 shares, bringing its total to 3,187,092 shares worth about $19.6 million. Meanwhile, Millennium Management LLC reduced its position by 69,579 shares, leaving it with 2,059,459 shares valued at approximately $12.7 million. Artisan Partners Limited Partnership also trimmed its stake by 98,580 shares, now holding 2,058,684 shares worth about $12.7 million. Nomura Holdings Inc. maintained its position with 2,000,060 shares valued at $12.3 million, while No Street GP LP slightly boosted its holdings by 25,000 shares to 2,000,000 shares worth $12.3 million. D. E. Shaw & Co., Inc. added 75,903 shares, ending with 1,959,732 shares valued at $12.1 million.

RxSight, Inc. Stock Snapshot

Shares of RxSight, Inc. are trading near $4.73. The company has a market capitalization of around $195.8 million. With a forward P/E ratio of -8.45, the company isn't currently profitable. The stock's beta is 1.134, indicating moderate volatility. Over the past year, the stock's price has ranged from a low of $4.48 to a high of $14.29. The 50-day moving average is $6.09, and the 200-day moving average is $8.36. RxSight, Inc. has a strong current ratio of 10.2 and a quick ratio of 8.779, with a debt-to-equity ratio of 4.05.

Analysts Set New Price Targets

On May 7, 2026, Wells Fargo maintained a hold rating on RxSight, Inc. with a $9 price target. The same day, Needham reiterated its buy rating with a target of $11. Stifel and UBS both maintained hold ratings, each setting a $9 target in earlier months. Piper Sandler kept its hold rating with a $10 target on February 26, 2026. The consensus target price stands at $8.79, based on seven analyst opinions.

About RxSight, Inc.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California. The company specializes in developing and selling light adjustable intraocular lenses used in cataract surgery. Their flagship product, the RxSight system, allows doctors to fine-tune patients' vision post-surgery using a light delivery device. Dr. Ronald M. Kurtz M.D. leads the company as CEO, and it employs 461 people.

Bottom Line

Julie Andrews and several other insiders have shown confidence in RxSight, Inc. by acquiring shares. The company, while not currently profitable, continues to adjust its position in the medical device sector. Investors often monitor these insider transactions as potential indicators of future performance. However, it's important to remember that these filings reflect past events and may not indicate current holdings or future actions.